mp.weixin.qq.com·· 19 hours agoPickScore84
2026 ESMO Abstracts Focus on Next Treatment After CDK4/6 Inhibitor Progression in Advanced Breast Cancer
In brief
Three 2026 ESMO abstracts address subsequent therapy for HR+/HER2− advanced breast cancer after progression on CDK4/6 inhibitors, covering atirmociclib, abemaciclib, and giredestrant combination regimens respectively.
Why it matters
Three ESMO abstracts cover PFS improvement, OS not reaching statistical significance, and biomarker stratification, providing data to compare post-progression options in the same disease setting.
Source: mp.weixin.qq.com · mp.weixin.qq.com